Transaction DateRecipientSharesTypePriceValue
19th July 2019Dmitry Genkin93,390Grant/award etc.$0.00
14th March 2018Dmitry Genkin29,452Other acquisition or disposition$0.00
Xenetic Biosciences
Xenetic Biosciences logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Xenetic Biosciences, Inc. is a biopharmaceutical company, which focuses on progressing XCART, a personalized CAR T platform technology. The company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's tumor cells.

Ticker: XBIO
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1534525
Employees: 4
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags